Rebecca Torrence’s Post

Thrilled to see Tempus, founded by Eric Lefkofsky, make such an impressive debut on Nasdaq, rising 9% despite previous valuation cuts. The company raised $411 million and is on a mission to revolutionize diagnostics with AI. Reflecting on the journey, it’s inspiring how Lefkofsky observed a need for data-driven treatment during his wife’s battle with cancer and transformed that vision into Tempus. It’s a powerful reminder of how personal experiences can ignite groundbreaking innovations. Here’s what stands out: - Tempus is embedding AI, including generative AI, in all its diagnostic tools. - Despite AI accounting for only 1% of 2023 revenue, there’s a clear commitment to growth in this area. - Lefkofsky expects the company to be cash-flow and EBITDA positive by 2025. Tempus is a testament to innovation in health tech. How do you see AI transforming healthcare in the next few years? #HealthTech #AI #Innovation #IPO #EricLefkofsky #Tempus

Atropos Health secured $33 million in Series B funding with a compelling 22-slide pitch deck for their innovative generative AI bot for doctors. - 🏥 Revolutionizing healthcare with AI - 📊 Data-driven insights for better patient outcomes - 💡 Empowering doctors with cutting-edge technology #HealthcareInnovation #AIinMedicine #TechFunding - The AI bot provides real-time, data-driven recommendations to doctors. - Focuses on enhancing decision-making in clinical settings. - Designed to integrate seamlessly with existing healthcare systems. - Aims to improve patient outcomes and streamline medical processes. - Attracts significant investor interest due to its transformative potential in healthcare. - Part of a growing trend of AI applications revolutionizing various industries. Here's the 22-slide pitch deck that got Atropos Health $33 million for its generative AI bot for doctors https://lnkd.in/gDMsxgSy

Be sure to catch this pitch from an SF-based startup at our April 19 Startup Showcase! AESOP Technology is about “Deep Clinical Reasoning AI” to improve the clinical decision-making process, enhance medical coding quality, and prioritize patient safety. Its “Patient Safety-Centric Product Portfolio” boasts 99% accuracy in identifying and analyzing data and integrating directly into physicians' clinical workflows. The AI approach it developed, called “DeepDRG,” unlocks understanding of how diagnoses are typically associated with structured clinical data like lab results, medications, and procedures. It makes documentation easier, faster, and less error-prone using Machine Learning on 3.2 billion patient visits. AESOP was a Mayo Platform_Accelerate startup in Cohort 2. It is not currently raising, but planning to as soon as late 2024.

Access to #clinical data and #RWD is critical to enhance #AI models used in #Drug #RnD, and should be combined with #discovery and #preclinical data when applicable.

A huge thank you to everyone who joined us for ConverSight's inaugural State of AI in Indiana. For those who missed it, here’s a quick recap of our panel discussion: 🏭 AI in Manufacturing and Distribution: Mehrdad Erfan covered use cases like AI vision systems and machine learning algorithms that are revolutionizing efficiency and quality control. The data processing power of AI is instrumental in up-skilling the workforce with augmented decision intelligence. 🏥 AI in Healthcare: The potential of GenAI in healthcare is immense. Benjamin Mansalis discussed innovations like ambient listening for clinical documentation and AI in medical imaging – vital tools enhancing patient care and efficiency. 🔍 AnalytiXIN: A key highlight was AnalytiXIN's commitment to advancing analytics and AI in Indiana. They're spearheading efforts in workforce development, fostering collaborations between industry and academia, and building communities of practice. For anyone looking to be a part of this initiative, reach out to Darshan Shah. 💡 Venture Capital Insights: Chelsea Linder shared that VC's across the US are laser-focused on foundational GenAI models. While Indiana is seeing a lot of post-product implementation of AI, the state is lagging in terms of venture capital dollars invested into AI companies as a whole, although this may change in the year to come. We're looking forward to growing this event in 2024, along with some quarterly conversations around focused topics. Reach out to me if you’re interested to get involved with future events and discussions around AI in Indiana.

Our team was fortunate to be able to sit down with Katie Jennings of Forbes to discuss the very immediate need to validate AI algorithms in healthcare before they are widely deployed on patient populations Dandelion is uniquely positioned to help in this due to the unprecedented level of fully anonymized real world data (10M+ records and fully multimodal from Sanford Health Sharp HealthCare Texas Health Resources) as well as the incredible work the Dandelion team have done to build out our validation product - https://lnkd.in/ePXU6Ai2. The issue of developing solutions, or insights, from data is not a new one but the capabilities of these products really change when you have a full view into what actually happened with patients over time. The great thing about AI is that we don't have to guess whether a product may work well - we can actually test it. This validation product (partly funded by the Gordon and Betty Moore Foundation and The SCAN Foundation) is the first step in building out our ultimate vision - a platform that is focused on product development in healthcare for those that wish to use truly high fidelity data to ensure they build accurate, differentiated products that have the best chance of improving patient lives / healthcare outcomes for all. https://lnkd.in/eAweHbPp #ai #validation #healthcareai #healthcaredata With thanks to: Sanford Health Sharp HealthCare Texas Health Resources Primary Venture Partners Convergent Ventures Floating Point Moxxie Ventures Forbes Katie Jennings Alistair johnson Jason Ma Kiko Wemmer Shivaani Prakash, MSc, PhD Nick Burke Ross Bierbryer Nicholas Gossen Sofia (Becerra) Van Dusen Nick Znajkowski Manqing L. Mara Alexeev Gonzalo Hernandez Neil Jethani Jamie Dermon, MD, CPHQ Mathilde Williams Maxence Frenette Owen Kasozi Isaac Moshe Sam Toole

The latest in our challenger brand series... This week, we’re here to talk BioTech. 🧬 More specifically the intersection between AI and BioTech. 💻 🧬 Meet CHARM Therapeutics who are unfolding the future of medicine through 3D deep learning technology. CHARM recently was showcased by CB Insights as one of the 100 most promising private AI companies of 2024. 🎉 By applying revolutionary insights to complex protein interactions (we know... 🤯) CHARM is targeting previously undruggable diseases. Pretty cool right? 👏 Led by Co-Founders Laksh Aithani and David Baker, and a team behind them with a track record in next-wave AI, CHARM is out to use AI and DeepLearning to transform how drugs are made. There will be a huge number of advances in the next five years and CHARM are most definitely paving the way for others to follow suit. ✅ If you want to understand more about Europe's burgeoning BioTech scene, then give our friends BACKED VC a following on LI. The VC fund are creating a blossoming community for all things BioTech, not least their #LONDONBIO events (and take full credit for this snap of Laksh). Full marks to Vinay Chaudhri & Clare Hunter! Here's to generating greater brand awareness for all things BioTech! 🧫 #BioCommunity #AI

🤖 Artificial Intelligence (AI) is used in some capacity in almost every industry. And it is truly taking off in health. Let's focus on clinical research and diagnostics, where speed is one of the key advantages of using AI. Consistency, accuracy, repeatability, and scalability are other critical benefits. 🏥 Our supported startup Spotlab has developed a platform (TeleSpot®) that finds solutions to clinical research challenges and diagnostic needs by speeding up the creation and deployment of AI models in clinical environments. This way AI can be leveraged for everyone, everywhere - from blood cancers to neglected tropical diseases. 🌟Discover more: https://www.spotlab.ai/   👏#WA4STEAM #businessangels are proud to support Spotlab's team led by MARIA POSTIGO CAMPS, Miguel Luengo-Oroz, Alexander Bakardjiev, Jose Nistal and Jaime García Villena in their endeavor to deliver the best science and technology for everyone, everywhere. #WA4STEAM is an all-women #businessangels association investing in #womenfounders in #steam. 👉🏻Visit www.wa4steam.com for information about the sectors our angels support, if our angels and your startup are a good match, and details on who we are.    #womensupportingwomen #democratisingbusinessangels #womenentrepreneurs #womenfounders #womenbusinessangels #wa4steam #womeninvestors #stem #STEAMfemenino Genoveva Ortiz, Susana Marcos, Ines Boronat, Sara Santolaria, Begoña García Almería, Rocío García Rubio, Flavia Bartolome Tocino, VISITACION DIAZ VARONA, Ana Lozano Portillo, Beni Cantos, Adela Martín Ruiz, Regina Llopis, Maria Maso, Ana García Rodríguez, Teresa Morales Muñoz, Carolina Rubio Miner, Julia Sánchez, Andrea Martinelli, Dolores Sarrion, LEONOR ARESTI, Mª José Rivero Menéndez, Nuria (纽瑞雅) Capdevila, Lourdes Nuñez-Müller, PhD, MBA, Maria Jose Manjon Rodriguez, Idoia Picossi, Ana Suárez Gamazo, Carmen Barcelo, Jessica Bolanos, Raquel Sánchez Aparicio, Lucrecia Palacios, Peña Lería, Carolina Pinart, Ph.D., Henar Martínez Torres

Nabla raises another $24 million for its AI assistant for doctors that automatically writes clinical notes | TechCrunch: Nabla, a Paris-based startup, has raised a $24 million Series B funding round. The company is developing an AI copilot for medical staff, providing real-time note-taking and report-writing capabilities. The tool uses speech-to-text technology to generate accurate medical reports and aims to assist doctors in saving time on administrative work. - Artificial Intelligence topics! #ai #artificialintelligence #intelligenzaartificiale

ARTIS Ventures is proud to announce the close of our latest $200 million fund, TechBio II, dedicated to deploying capital wherever data, software, AI, machine learning, and deep learning transform human health and well-being. We stand at the dawn of a new era—the age of TechBio—that will transform health and medicine. For the first time, innovations in technology, healthcare, and biology are converging to offer groundbreaking solutions to humanity's greatest medical challenges. We continue to make a firm-wide commitment to TechBio and are excited to fund and support its next generation of founders and startups. These early-stage companies embody the prospect of revolutionary innovation, and we believe the best among them will forever change the landscapes of healthcare and biology, creating not only immense value but, most importantly, significant societal impact. Read more about it on our blog: https://lnkd.in/dG-h-VRC Stuart Peterson Vasudev Bailey Austin Walne Ameena El-Bibany Zoe Guttendorf Henry Klingenstein Megan Daugherty Rob Riemer Jeffrey B. Kindler #TechBio #venturecapital #healthcare #lifescience #technology #engineering #ai #data